Eli Lilly and Company

Healthcare · Drug Manufacturers - General

Overall research band Mixed

Quality Strong

Valuation Very weak

Balance sheet Above average

Market confirmation Mixed

One-minute company read

What this report can tell you now

What the company does

Eli Lilly and Company is a global pharmaceutical firm headquartered in Indianapolis, Indiana, focused on the research, development, and commercialization of human medicines. Its main products include a wide range of diabetes treatments such as Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity; oncology drugs like Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio; autoimmune and inflammatory disease treatments including Olumiant and Taltz; neurological and pain management medications such as Cymbalta, Emgality, and Zyprexa; COVID-19 therapies like Bamlanivimab, etesevimab, and Bebtelovimab; as well as Cialis for erectile dysfunction and Forteo for osteoporosis. The company serves patients worldwide and generates revenue primarily through the sale of its prescription medicines. Eli Lilly collaborates with various partners, including Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, AbCellera Biologics, Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Kumquat Biosciences, Entos Pharmaceuticals, and Foghorn Therapeutics.

The current research profile is Premium Growth, with strong market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Business quality is the strongest visible dimension. Check valuation before treating that strength as an investment conclusion.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC44.8%Model input; read with the evidence status and period context.

Operating margin45.6%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years23.2%Model input; read with the evidence status and period context.

FCF margin13.8%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

This company is part of our public Premium preview.

View the full Premium report →